Published in Medical Letter on the CDC and FDA, September 16th, 2007
CORDAPTIVE is an investigational compound containing Merck's own extended-release niacin and laropiprant, a novel flushing pathway inhibitor designed to reduce flushing often associated with niacin treatment. Data included in the application support the proposed use of CORDAPTIVE, either alone or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA